
## JosÃ<sup>®</sup>ntonio LÓpez-Guerrero

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5922325/publications.pdf

Version: 2024-02-01



JosÉ Antonio

#	Article	IF	CITATIONS
1	Deletions Affecting Codons 557-558 of the c-KIT Gene Indicate a Poor Prognosis in Patients With Completely Resected Gastrointestinal Stromal Tumors: A Study by the Spanish Group for Sarcoma Research (GEIS). Journal of Clinical Oncology, 2005, 23, 6190-6198.	0.8	336
2	The Genomic Landscape of the Ewing Sarcoma Family of Tumors Reveals Recurrent STAG2 Mutation. PLoS Genetics, 2014, 10, e1004475.	1.5	335
3	Clinicopathological and immunohistochemical analysis of 20 cases of Merkel cell carcinoma in search of prognostic markers. Histopathology, 2005, 46, 622-634.	1.6	221
4	Dermatofibrosarcoma protuberans: a comprehensive review and update on diagnosis and management. Seminars in Diagnostic Pathology, 2013, 30, 13-28.	1.0	208
5	Histological heterogeneity of Ewing's sarcoma/PNET: an immunohistochemical analysis of 415 genetically confirmed cases with clinical support. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2009, 455, 397-411.	1.4	181
6	Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling. Oncogene, 2011, 30, 2730-2740.	2.6	119
7	GEIS guidelines for gastrointestinal sarcomas (GIST). Cancer Treatment Reviews, 2017, 55, 107-119.	3.4	114
8	Dermatofibrosarcoma protuberans: clinical, pathological, and genetic ( <i>COL1A1â€₽DGFB </i> ) study with therapeutic implications. Histopathology, 2009, 54, 860-872.	1.6	112
9	DNA Source Selection for Downstream Applications Based on DNA Quality Indicators Analysis. Biopreservation and Biobanking, 2016, 14, 264-270.	0.5	110
10	Identification of miR-187 and miR-182 as Biomarkers of Early Diagnosis and Prognosis in Patients with Prostate Cancer Treated with Radical Prostatectomy. Journal of Urology, 2014, 192, 252-259.	0.2	109
11	Dermatofibrosarcoma protuberans: AÂclinicopathological, immunohistochemical, genetic () Tj ETQq1 1 0.784314 Journal of the American Academy of Dermatology, 2011, 65, 564-575.	4 rgBT /O\ 0.6	verlock 10 Tf 92
12	Immunohistochemical Expression of Ki-67 Antigen, Cox-2 and Bax/Bcl-2 in Prostate Cancer; Prognostic Value in Biopsies and Radical Prostatectomy Specimens. European Urology, 2005, 48, 745-751.	0.9	82
13	Molecular Diagnosis of Ewing Sarcoma Family of Tumors. Diagnostic Molecular Pathology, 2009, 18, 189-199.	2.1	82
14	Molecular Analysis of the 9p21 Locus and p53 Genes in Ewing Family Tumors. Laboratory Investigation, 2001, 81, 803-814.	1.7	80
15	High stability of microRNAs in tissue samples of compromised quality. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 463, 765-774.	1.4	78
16	Shared Oncogenic Pathways Implicated in Both Virus-Positive and UV-Induced Merkel Cell Carcinomas. Journal of Investigative Dermatology, 2017, 137, 197-206.	0.3	78
17	A unique set of 6 circulating microRNAs for early detection of non-small cell lung cancer. Oncotarget, 2016, 7, 37250-37259.	0.8	77
18	Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients. Seminars in Oncology, 2017, 44, 187-197.	0.8	76

#	Article	IF	CITATIONS
19	Molecular diagnosis of dermatofibrosarcoma protuberans: A comparison between reverse transcriptaseã€polymerase chain reaction and fluorescence in situ hybridization methodologies. Genes Chromosomes and Cancer, 2011, 50, 510-517.	1.5	69
20	Molecular and Immunohistochemical Analysis of the Prognostic Value of Cell-Cycle Regulators in Urothelial Neoplasms of the Bladder. European Urology, 2006, 50, 506-515.	0.9	67
21	A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole. BMC Cancer, 2010, 10, 36.	1.1	67
22	Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study. Annals of Oncology, 2010, 21, 1552-1557.	0.6	64
23	Membrane Rafts: Portals for Viral Entry. Frontiers in Microbiology, 2021, 12, 631274.	1.5	64
24	Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study. Journal of Clinical Oncology, 2016, 34, 2294-2302.	0.8	61
25	Frequent <i>DPH3</i> promoter mutations in skin cancers. Oncotarget, 2015, 6, 35922-35930.	0.8	60
26	Array comparative genomic hybridization analysis of chromosomal imbalances and their target genes in gastrointestinal stromal tumors. Genes Chromosomes and Cancer, 2007, 46, 564-576.	1.5	59
27	Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: Focus on trabectedin. Cancer Treatment Reviews, 2014, 40, 366-375.	3.4	58
28	Establishment and Characterization of a Continuous Human Chondrosarcoma Cell Line, ch-2879: Comparative Histologic and Genetic Studies with Its Tumor of Origin. Laboratory Investigation, 2003, 83, 877-887.	1.7	54
29	Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing's sarcoma family of tumors (ESFT). Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 815-824.	1.4	53
30	MiR-187 Targets the Androgen-Regulated Gene ALDH1A3 in Prostate Cancer. PLoS ONE, 2015, 10, e0125576.	1.1	52
31	Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed Ewing's Sarcoma Family of Tumors. International Journal of Cancer, 2011, 128, 1139-1150.	2.3	51
32	Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial. Lancet Oncology, The, 2020, 21, 456-466.	5.1	51
33	Non-invasive urinary metabolomic profiling discriminates prostate cancer from benign prostatic hyperplasia. Metabolomics, 2017, 13, 52.	1.4	50
34	Expression of insulin-like growth factor system components in Ewing's sarcoma and their association with survival. European Journal of Cancer, 2011, 47, 1258-1266.	1.3	49
35	Deregulation of the G1 to S-Phase Cell Cycle Checkpoint Is Involved in the Pathogenesis of Human Osteosarcoma. Diagnostic Molecular Pathology, 2004, 13, 81-91.	2.1	46
36	Clinical Implications of TMPRSS2-ERG Gene Fusion Expression in Patients With Prostate Cancer Treated With Radical Prostatectomy. Journal of Urology, 2010, 183, 2054-2061.	0.2	45

#	Article	IF	CITATIONS
37	miRNAs as biomarkers in prostate cancer. Clinical and Translational Oncology, 2012, 14, 803-811.	1.2	45
38	Mismatch Repair Deficiency in Ovarian Carcinoma. American Journal of Surgical Pathology, 2020, 44, 649-656.	2.1	44
39	Clinico-pathological significance of the molecular alterations of the SPOP gene in prostate cancer. European Journal of Cancer, 2014, 50, 2994-3002.	1.3	43
40	GEIS 2013 guidelines for gastrointestinal sarcomas (GIST). Cancer Chemotherapy and Pharmacology, 2014, 74, 883-898.	1.1	42
41	Metabolomics Contributions to the Discovery of Prostate Cancer Biomarkers. Metabolites, 2019, 9, 48.	1.3	38
42	Electron microscopy and other ancillary techniques in the diagnosis of small round cell tumors. Seminars in Diagnostic Pathology, 2003, 20, 25-45.	1.0	37
43	Phenotyping and susceptibility of established porcine cells lines to African Swine Fever Virus infection and viral production. Scientific Reports, 2017, 7, 10369.	1.6	36
44	Use of Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) for Carcinoembryonic Antigen, Cytokeratin 19, and Maspin in the Detection of Tumor Cells in Leukapheresis Products from Patients with Breast Cancer: Comparison with Immunocytochemistry. Stem Cells and Development, 1999, 8, 53-61.	1.0	34
45	Minimal illegitimate levels of cytokeratin K19 expression in mononucleated blood cells detected by a reverse transcription PCR method (RT-PCR). Clinica Chimica Acta, 1997, 263, 105-116.	0.5	33
46	Low levels of WWOX protein immunoexpression correlate with tumour grade and a less favourable outcome in patients with urinary bladder tumours. Histopathology, 2008, 52, 831-839.	1.6	33
47	Clinical implications of KIT and PDGFRA genotyping in GIST. Clinical and Translational Oncology, 2010, 12, 670-676.	1.2	33
48	Imatinib plus lowâ€dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to highâ€dose imatinib. Cancer, 2010, 116, 3692-3701.	2.0	33
49	Prognostic relevance of CCN3 in Ewing sarcoma. Human Pathology, 2009, 40, 1479-1486.	1.1	32
50	Genome wide DNA methylation profiling identifies specific epigenetic features in high-risk cutaneous squamous cell carcinoma. PLoS ONE, 2019, 14, e0223341.	1.1	32
51	An integrated analysis of miRNA and gene copy numbers in xenografts of Ewing's sarcoma. Journal of Experimental and Clinical Cancer Research, 2012, 31, 24.	3.5	31
52	Novel and recurrent BRCA1/BRCA2 mutations in early onset and familial breast and ovarian cancer detected in the Program of Genetic Counseling in Cancer of Valencian Community (eastern Spain). Relationship of family phenotypes with mutation prevalence. Familial Cancer, 2013, 12, 767-777.	0.9	31
53	Prognostic classification of endometrial cancer using a molecular approach based on a twelve-gene NGS panel. Scientific Reports, 2019, 9, 18093.	1.6	31
54	Molecular Heterogeneity of Endometrioid Ovarian Carcinoma. American Journal of Surgical Pathology, 2020, 44, 982-990.	2.1	31

#	Article	IF	CITATIONS
55	MRP1 Overexpression Determines Poor Prognosis in Prospectively Treated Patients with Localized High-Risk Soft Tissue Sarcoma of Limbs and Trunk Wall: An ISG/GEIS Study. Molecular Cancer Therapeutics, 2014, 13, 249-259.	1.9	30
56	CCL27–CCR10 and CXCL12–CXCR4 chemokine ligand-receptor mRNA expression ratio: new predictive factors of tumor progression in cutaneous malignant melanoma. Clinical and Experimental Metastasis, 2012, 29, 625-637.	1.7	27
57	p16INK4A(CDKN2A) Gene Deletion Is a Frequent Genetic Event in Synovial Sarcomas. American Journal of Clinical Pathology, 2006, 126, 866-874.	0.4	25
58	A de novo complete BRCA1 gene deletion identified in a Spanish woman with early bilateral breast cancer. BMC Medical Genetics, 2011, 12, 134.	2.1	25
59	The Effect of Cellular Differentiation on HSV-1 Infection of Oligodendrocytic Cells. PLoS ONE, 2014, 9, e89141.	1.1	25
60	Desmoplastic infantile ganglioglioma. Morphological, immunohistochemical and genetic features. Histopathology, 2006, 48, 617-621.	1.6	24
61	Subcutaneous dermatofibrosarcoma protuberans, a rare subtype with predilection for the head: A retrospective series of 18 cases. Journal of the American Academy of Dermatology, 2017, 77, 503-511.e1.	0.6	24
62	Immunohistochemical analysis of NKX2.2, ETV4, and BCOR in a large series of genetically confirmed Ewing sarcoma family of tumors. Pathology Research and Practice, 2017, 213, 1048-1053.	1.0	24
63	Epithelial marker expression does not rule out a diagnosis of Ewing's sarcoma family of tumours. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 459, 409-414.	1.4	22
64	Epithelial cell adhesion molecules and epithelial mesenchymal transition (EMT) markers in Ewing's sarcoma family of tumors (ESFTs). Do they offer any prognostic significance?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 461, 333-337.	1.4	21
65	Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cance. Chinese Journal of Cancer, 2015, 34, 41-49.	4.9	21
66	The Frequency and Prognostic Significance of the Histologic Type in Early-stage Ovarian Carcinoma. American Journal of Surgical Pathology, 2020, 44, 149-161.	2.1	21
67	RG7112, a Small-Molecule Inhibitor of MDM2, Enhances Trabectedin Response in Soft Tissue Sarcomas. Cancer Investigation, 2015, 33, 440-450.	0.6	20
68	HER2 amplification in recurrent breast cancer following breast-conserving therapy correlates with distant metastasis and poor survival. International Journal of Cancer, 2006, 118, 1743-1749.	2.3	19
69	Mutational Analysis of the c-KIT AND PDGFR?? in a Series of Molecularly Well-Characterized Synovial Sarcomas. Diagnostic Molecular Pathology, 2005, 14, 134-139.	2.1	18
70	Galectin-1 (GAL-1) expression is a useful tool to differentiate between small cell osteosarcoma and Ewing sarcoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 462, 665-671.	1.4	18
71	Gastrointestinal stromal tumors (CISTs): SEAP–SEOM consensus on pathologic and molecular diagnosis. Clinical and Translational Oncology, 2017, 19, 536-545.	1.2	18
72	ERG deregulation induces IGF-1R expression in prostate cancer cells and affects sensitivity to anti-IGF-1R agents. Oncotarget, 2015, 6, 16611-16622.	0.8	18

#	Article	IF	CITATIONS
73	p16INK4A and p15INK4B Gene Alteration Associated with Oxidative Stress in Renal Cell Carcinomas After the Chernobyl Accident (Pilot Study). Diagnostic Molecular Pathology, 2002, 11, 163-169.	2.1	17
74	Outcomes of expanded use of PCA3 testing in a Spanish population with clinical suspicion of prostate cancer. Actas Urológicas Españolas (English Edition), 2011, 35, 589-596.	0.2	17
75	Frequent deletion of <i>CDKN2A</i> and recurrent coamplification of <i>KIT</i> , <i>PDGFRA</i> , and <i>KDR</i> in fibrosarcoma of bone—An array comparative genomic hybridization study. Genes Chromosomes and Cancer, 2010, 49, 132-143.	1.5	16
76	Cytochrome P17 Inhibition With Ketoconazole As Treatment for Advanced Granulosa Cell Ovarian Tumor. Journal of Clinical Oncology, 2013, 31, e165-e166.	0.8	16
77	The early stages of tumor angiogenesis in human osteosarcoma: a nude mice xenotransplant model. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 467, 193-201.	1.4	16
78	Atypical Pleomorphic Extraosseous Ewing Tumor/Peripheral Primitive Neuroectodermal Tumor with Unusual Phenotypic/Genotypic Profile. Diagnostic Molecular Pathology, 2002, 11, 9-15.	2.1	15
79	The INK4a/ARF locus: role in cell cycle control for renal cell epithelial tumor growth after the Chernobyl accident. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 445, 298-304.	1.4	15
80	Characterization of the MAL2-positive compartment in oligodendrocytes. Experimental Cell Research, 2009, 315, 3453-3465.	1.2	15
81	Prostate cancer: The revolution of the fusion genes. Actas Urológicas Españolas (English Edition), 2011, 35, 420-428.	0.2	15
82	Characterization of a New Human Cell Line (CH-3573) Derived from a Grade II Chondrosarcoma with Matrix Production. Pathology and Oncology Research, 2012, 18, 793-802.	0.9	15
83	Optimizing the clinical utility of PCA3 to diagnose prostate cancer in initial prostate biopsy. BMC Cancer, 2015, 15, 633.	1.1	15
84	Cytogenetic and molecular findings related to rhabdomyosarcoma. An analysis of seven cases. Cancer Genetics and Cytogenetics, 2003, 144, 125-133.	1.0	14
85	Tissue microarray profiling of primary and xenotransplanted synovial sarcomas demonstrates the immunophenotypic similarities existing between SYT-SSX fusion gene confirmed, biphasic, and monophasic fibrous variants. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 449, 435-447.	1.4	14
86	Evaluation of genetic stability of the SYT gene rearrangement by break-apart FISH in primary and xenotransplanted synovial sarcomas. Cancer Genetics and Cytogenetics, 2007, 172, 23-28.	1.0	14
87	Inflammatory fibroid polyp of the small bowel with a mutation in exon 12 of PDGFRα. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2009, 454, 327-331.	1.4	14
88	Targeted Metabolomics Analyses Reveal Specific Metabolic Alterations in High-Grade Prostate Cancer Patients. Journal of Proteome Research, 2020, 19, 4082-4092.	1.8	14
89	Optimizing sharing of hospital biobank samples. Science Translational Medicine, 2015, 7, 297fs31.	5.8	13
90	Suitability of melanoma FFPE samples for NGS libraries: time and quality thresholds for downstream molecular tests. BioTechniques, 2018, 65, 79-85.	0.8	13

#	Article	IF	CITATIONS
91	Implementation of massive sequencing in the genetic diagnosis of hereditary cancer syndromes: diagnostic performance in the Hereditary Cancer Programme of the Valencia Community (FamCan-NGS). Hereditary Cancer in Clinical Practice, 2019, 17, 3.	0.6	13
92	Evaluation of Prognostic Factors and Their Capacity to Predict Biological Behavior in Gastrointestinal Stromal Tumors. International Journal of Surgical Pathology, 2011, 19, 448-461.	0.4	12
93	Metastatic Lesions with and without Interleukin-18–Dependent Genes in Advanced-Stage Melanoma Patients. American Journal of Pathology, 2013, 183, 69-82.	1.9	12
94	A new risk variant for multiple sclerosis at the immunoglobulin heavy chain locus associates with intrathecal IgG, IgM index and oligoclonal bands. Multiple Sclerosis Journal, 2015, 21, 1104-1111.	1.4	12
95	Primary Cutaneous Leiomyosarcoma Arising in a Patient With Li-Fraumeni Syndrome: A Neoplasm With Unusual Histopathologic Features and Loss of Heterozygosity at TP53 Gene. American Journal of Dermatopathology, 2018, 40, 225-227.	0.3	12
96	A germline mutation of p14/ARF in a melanoma kindred. Melanoma Research, 2009, 19, 335-337.	0.6	11
97	Relationship of immunohistochemistry, copy number aberrations and epigenetic disorders with BRCAness pattern in hereditary and sporadic breast cancer. Familial Cancer, 2016, 15, 193-200.	0.9	11
98	Germline mutations in CDKN2A are infrequent in female patients with melanoma and breast cancer. Melanoma Research, 2009, 19, 211-214.	0.6	10
99	Insulin-like growth factor 1 receptor affects the survival of primary prostate cancer patients depending on TMPRSS2-ERG status. BMC Cancer, 2017, 17, 367.	1.1	10
100	A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors. Scientific Reports, 2021, 11, 4433.	1.6	10
101	Active Surveillance in Prostate Cancer: Role of Available Biomarkers in Daily Practice. International Journal of Molecular Sciences, 2021, 22, 6266.	1.8	10
102	Interaction of PLP with GFP-MAL2 in the Human Oligodendroglial Cell Line HOG. PLoS ONE, 2011, 6, e19388.	1.1	10
103	Dermatofibrosarcoma protuberante en la infancia. Piel, 2006, 21, 435-441.	0.0	9
104	GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012. Clinical and Translational Oncology, 2013, 15, 509-525.	1.2	9
105	The hallmarks of ovarian cancer: Focus on angiogenesis and micro-environment and new models for their characterisation. European Journal of Cancer, Supplement, 2020, 15, 49-55.	2.2	9
106	A Tetra-Panel of Serum Circulating miRNAs for the Diagnosis of the Four Most Prevalent Tumor Types. International Journal of Molecular Sciences, 2020, 21, 2783.	1.8	9
107	Structural Basis of Tumoral Angiogenesis. Advances in Experimental Medicine and Biology, 2003, 532, 69-89.	0.8	9
108	Disruption of basement membrane, extracellular matrix metalloproteinases and E-cadherin in renal-cell carcinoma. Anticancer Research, 2003, 23, 5005-10.	0.5	9

#	Article	IF	CITATIONS
109	Validation of a 2â€gene mRNA urine test for the detection of ≥GG2 prostate cancer in an opportunistic screening population. Prostate, 2020, 80, 500-507.	1.2	8
110	Isolation and characterization of urine microvesicles from prostate cancer patients: different approaches, different visions. BMC Urology, 2021, 21, 137.	0.6	8
111	Age, sex and co-exposure to N-ethyl-N-nitrosourea influence mutations in the Alu repeat sequences in diethylstilbestrol-induced kidney tumors in Syrian hamsters. Mutagenesis, 2004, 19, 67-73.	1.0	7
112	Alterations of ubiquitylation and sumoylation in conventional renal cell carcinomas after the Chernobyl accident: a comparison with Spanish cases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 459, 307-313.	1.4	7
113	Biomarkers in the Ewing sarcoma family of tumors. Current Biomarker Findings, 2014, Volume 4, 81-92.	0.4	7
114	Prognostic Impact of let-7e MicroRNA and Its Target Genes in Localized High-Risk Intestinal GIST: A Spanish Group for Research on Sarcoma (GEIS) Study. Cancers, 2020, 12, 2979.	1.7	7
115	The hallmarks of ovarian cancer: proliferation and cell growth. European Journal of Cancer, Supplement, 2020, 15, 27-37.	2.2	7
116	Role of Proteolipid Protein in HSV-1 Entry in Oligodendrocytic Cells. PLoS ONE, 2016, 11, e0147885.	1.1	7
117	Angiosarcomas: histology, immunohistochemistry and molecular insights with implications for differential diagnosis. Histology and Histopathology, 2021, 36, 3-18.	0.5	7
118	Extracellular Polymeric Substances: Still Promising Antivirals. Viruses, 2022, 14, 1337.	1.5	7
119	The type of reverse transcriptase affects the sensitivity of some reverse transcription PCR methods. Clinica Chimica Acta, 1997, 260, 73-83.	0.5	6
120	C-erbB-2 expression and its relationship with ploidy, p53 abnormalities and epidermal growth factor receptor content in human non-small cell lung cancer. Clinica Chimica Acta, 1999, 285, 105-120.	0.5	6
121	CIST: Particular aspects related to cell cultures, xenografts, and cytogenetics. Seminars in Diagnostic Pathology, 2006, 23, 103-110.	1.0	6
122	Chronic lymphocytic leukemia with isochromosome 17q: An aggressive subgroup associated with TP53 mutations and complex karyotypes. Cancer Letters, 2017, 409, 42-48.	3.2	6
123	CDKN2A germline alterations in melanoma patients with personal or familial history of pancreatic cancer. Melanoma Research, 2018, 28, 246-249.	0.6	6
124	Detection of miRNA cancer biomarkers using light activated Molecular Beacons. RSC Advances, 2019, 9, 12766-12783.	1.7	6
125	CUL4A, ERCC5, and ERCC1 as Predictive Factors for Trabectedin Efficacy in Advanced Soft Tissue Sarcomas (STS): A Spanish Group for Sarcoma Research (GEIS) Study. Cancers, 2020, 12, 1128.	1.7	6
126	Histological tumor grade correlates with HER2/c-erB-2 status in invasive breast cancer: a comparative analysis between immunohistochemical (CB11 clone and Herceptest), FISH and differential PCR procedures. Arkhiv Patologii, 2003, 65, 50-5.	0.0	6

#	Article	IF	CITATIONS
127	Relationship of p53 molecular abnormalities with flow cytometry and growth factor receptor content in lung cancer. Clinica Chimica Acta, 1998, 269, 63-76.	0.5	5
128	Biphasic dermatofibrosarcoma protuberans with a labyrinthine plexiform high-grade fibrosarcomatous transformation. Journal of Cutaneous Pathology, 2015, 42, 206-212.	0.7	5
129	Neuroendocrine differentiation in a large series of genetically-confirmed Ewing's sarcoma family tumor: Does it provide any diagnostic or prognostic information?. Pathology Research and Practice, 2021, 219, 153362.	1.0	5
130	Mutational Characterization of Cutaneous Melanoma Supports Divergent Pathways Model for Melanoma Development. Cancers, 2021, 13, 5219.	1.7	5
131	Does PAX7 and NKX2.2 immunoreactivity in Ewing sarcoma have prognostic significance?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 909-917.	1.4	5
132	Estrogen-Induced Mutations and Its Role in the Development of Tumorigenesis. , 2005, , 475-479.		4
133	Value of the identification of microsatellite instability in colorectal cancer. Clinical and Translational Oncology, 2009, 11, 465-469.	1.2	4
134	Clinical Significance of Tumor Protein D52 Immunostaining in a Large Series of Ewing's Sarcoma Family of Tumors. Pediatric and Developmental Pathology, 2011, 14, 255-256.	0.5	4
135	Real-world experience with trabectedin for the treatment of recurrent ovarian cancer. Expert Review of Anticancer Therapy, 2021, 21, 1089-1095.	1.1	4
136	Locoregional relapse in BRCA1/2 breast cancer women treated with breast-conserving surgery Journal of Clinical Oncology, 2016, 34, 1527-1527.	0.8	4
137	Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study. Cancers, 2022, 14, 915.	1.7	4
138	Tissue microarrays: applications in study of p16 and p53 alterations in Ewing's cell lines. Diagnostic Pathology, 2008, 3, S27.	0.9	3
139	Chemokine Expression Is Involved in the Vascular Neogenesis of Ewing Sarcoma: A Preliminary Analysis of the Early Stages of Angiogenesis in a Xenograft Model. Pediatric and Developmental Pathology, 2019, 22, 30-39.	0.5	3
140	The Importance of Biobanks in Epigenetic Studies. , 2016, , 19-35.		2
141	High-risk gastrointestinal stromal tumour (GIST) and synovial sarcoma display similar angiogenic profiles: a nude mice xenograft study. Ecancermedicalscience, 2017, 11, 726.	0.6	2
142	Prognostic/predictive biomarkers in advanced soft tissue sarcomas (STS): Translational research associated to randomized phase II trial comparing trabectedin-doxorubicin versus doxorubicin—A GEIS study Journal of Clinical Oncology, 2014, 32, 10500-10500.	0.8	2
143	<i>CUL4A and ERCC1</i> genesas predictive factors for trabectedin efficacy in advanced soft tissue sarcomas (STS): A Spanish Group for Sarcoma Research (GEIS) study Journal of Clinical Oncology, 2016, 34, 11048-11048.	0.8	2
144	Phase I study to evaluate the tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) of PM01183 (Lurbinectedin) in combination with olaparib in patients with advanced solid tumors Journal of Clinical Oncology, 2017, 35, 5573-5573.	0.8	2

#	Article	IF	CITATIONS
145	Central pathology review of early-stage ovarian carcinoma: Description and correlation with follow-up—A study by the Spanish Group for Ovarian Cancer Research (GEICO) Journal of Clinical Oncology, 2014, 32, 5583-5583.	0.8	2
146	Expression profiles of angiogenesis in two high grade chondrosarcomas: A xenotransplant experience in nude mice. Histology and Histopathology, 2017, 32, 1281-1291.	0.5	2
147	Valor de la expresión inmunohistoquÃmica de CD117 y del estudio molecular de c-KIT y PDGFRα en la redefinición diagnóstica de una serie retrospectiva de tumores mesenquimales del tracto gastrointestinal. Revista Espanola De Patologia, 2010, 43, 139-143.	0.6	1
148	Relationship of <i>CUL4A </i> gene underexpression and prognosis in localized high-risk soft tissue sarcoma (STS) patients of limbs or trunk wall. Journal of Clinical Oncology, 2012, 30, 10079-10079.	0.8	1
149	Disregulation of <i>mir-550</i> and <i>let-7e</i> in intestinal high-risk localized GIST: A GEIS study Journal of Clinical Oncology, 2014, 32, 10514-10514.	0.8	1
150	Genomic characterization of high-grade serous ovarian Cancer by using targeted RNA and DNAseq gene panels Journal of Clinical Oncology, 2016, 34, e17060-e17060.	0.8	1
151	Open label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: The Greko II study Journal of Clinical Oncology, 2017, 35, 5577-5577.	0.8	1
152	Gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients. Oncotarget, 2018, 9, 17576-17588.	0.8	1
153	Early stage ovarian cancer clinical behavior according to FIGO 2014 Staging changes with a focus on IC subtype: data from prospective GEICO registry Journal of Clinical Oncology, 2015, 33, 5554-5554.	0.8	1
154	Evaluation of systemic and local immune responses in patients with endometrial cancer Journal of Clinical Oncology, 2017, 35, 5594-5594.	0.8	1
155	Clinicopathological significance and prognostic value of intratumoral and peritumoral lymphocytes in endometrial cancer patients Journal of Clinical Oncology, 2019, 37, e17116-e17116.	0.8	1
156	Prospective Real-World Gynaecological Cancer Clinical Registry with Associated Biospecimens: A Collaborative Model to Promote Translational Research between GEICO and the Spanish Biobank Network. Cancers, 2022, 14, 1965.	1.7	1
157	Análisis morfométrico y contenido de ADN en el nevo displásico. Estudio comparativo frente a otras lesiones melanocÃŧicas benignas. Actas Dermo-sifiliográficas, 2004, 95, 97-103.	0.2	Ο
158	Genetic Counseling in Renal Masses. Advances in Urology, 2008, 2008, 1-12.	0.6	0
159	Locally advanced dermatofibrosarcoma protuberans treated with imatinib followed by Mohs surgery: Results of six cases of a single institution. Journal of the American Academy of Dermatology, 2010, 62, AB107.	0.6	0
160	Linfoma de Hodgkin con presencia de t(14;18) en paciente con antecedentes de linfoma folicular. Revista Espanola De Patologia, 2013, 46, 106-111.	0.6	0
161	MP28-16 EXPRESSION OF KRT20 AND FXYD3 GENES IN PN0 AND CLINICAL RELEVANCE IN PATIENTS TREATED WITH RADICAL CYSTECTOMY AND LYMPHADENECTOMY FOR BLADDER CANCER. Journal of Urology, 2014, 191, .	0.2	0
162	Histological factors predicting loco-regional lymph node metastasis in early invasive colorectal adenocarcinoma pT1. GastroenterologÃa Y HepatologÃa (English Edition), 2016, 39, 1-8.	0.0	0

#	Article	IF	CITATIONS
163	MamaPred: A new and innovative approach to determine recurrence risk in HR+/HER2- early-stage breast cancer using HTG EdgeSeq technology Journal of Clinical Oncology, 2021, 39, 558-558.	0.8	0
164	Inflammatory indexes neutrophils/lymphocytes, platelets/lymphocytes and red-cell distribution width (RDW) as prognostic biomarkers in advanced solitary fibrous tumors (SFT) treated with pazopanib: Correlative study of GEIS-32 trial Journal of Clinical Oncology, 2021, 39, 11511-11511.	0.8	0
165	Laboratory cross-comparison of homologous recombination repair mutation analysis in tumor in a multicenter epithelial ovarian cancer series: The BORNEO GEICO 60-0 study Journal of Clinical Oncology, 2021, 39, e17550-e17550.	0.8	0
166	Prognostic Relevance of CCN3 in Bone Sarcomas. , 2010, , 223-243.		0
167	Angiogenesis biomarker study of a phase II trial of pazopanib (P) in recurrent or persistent ovarian (EOC), peritoneal (PPC), or fallopian tube cancer (FTC): A Spanish Ovarian Cancer Group (GEICO) study Journal of Clinical Oncology, 2012, 30, e15575-e15575.	0.8	0
168	MicroRNA profiling analysis in a series of high-risk intestinal GISTs Journal of Clinical Oncology, 2013, 31, 10532-10532.	0.8	0
169	Prospective correlation between clinical and pathologic criteria identification of Lynch syndrome (LS) in endometrial carcinoma (EC) patients and relapse Journal of Clinical Oncology, 2013, 31, 1543-1543.	0.8	0
170	Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced nonresectable granulosa cell ovarian tumors: The GREKO II study Journal of Clinical Oncology, 2014, 32, TPS5626-TPS5626.	0.8	0
171	Ketoconazole as inhibitor of the enzyme CYP17 in locally advanced or disseminated granulosa cell tumors of the ovary (the GreKo I study) (gethi 11-03) Journal of Clinical Oncology, 2014, 32, 5558-5558.	0.8	0
172	Abstract 2863: TMPRSS2-ERG influences IGF-1R expression and affects its prognostic value in prostate cancer. , 2014, , .		0
173	Clinicopathological Significance of Taz and VGLL1 Expression in Early Stage Ovarian Cancer. A study by Spanish Group for Ovarian Cancer Research (GEICO) Journal of Clinical Oncology, 2015, 33, e16583-e16583.	0.8	0
174	Perfomance of identification criteria for Lynch syndrome (LS) in a prospective population-based registry of Endometrial Cancer (EC): Prognostic value Journal of Clinical Oncology, 2015, 33, e16516-e16516.	0.8	0
175	Prognostic relevance of miRNA let-7e in localized intestinal GIST: A Spanish Group for Research on Sarcoma (GEIS) Study Journal of Clinical Oncology, 2015, 33, 10524-10524.	0.8	0
176	Prospective comparison of different methods of identifying Lynch Syndrome (LS) associated endometrial cancer (EC) and prognostic factor (PF) impact Journal of Clinical Oncology, 2016, 34, e17102-e17102.	0.8	0
177	Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced nonresectable granulosa cell ovarian tumors: The GREKO II study Journal of Clinical Oncology, 2016, 34, TPS2598-TPS2598.	0.8	0
178	Evaluating a novel oncologist-led <i>BRCA1/2</i> mutation ( <i>BRCA</i> m) testing counseling model for patients with ovarian cancer: Interim results from the ENGAGE study Journal of Clinical Oncology, 2016, 34, e17048-e17048.	0.8	0
179	Prognostic impact of COL5A2 and ACVR1B genes in intestinal high risk localized GIST. A Spanish Group for Research on Sarcoma (GEIS) study Journal of Clinical Oncology, 2016, 34, e22514-e22514.	0.8	0
180	Phosphatidylinositol-4, 5-biphosphate 3-kinase, catalytic subunit alpha ( <i>PI3KCA)</i> and microsatellite instability in ovarian clear cell carcinoma, clinical correlation Journal of Clinical Oncology, 2016, 34, e17061-e17061.	0.8	0

#	Article	IF	CITATIONS
181	CD8+ TILs in early stage epithelial ovarian cancer: A GEICO study Journal of Clinical Oncology, 2017, 35, 5543-5543.	0.8	Ο
182	Characterization of differential genetic expression profiles in mesenchymal and epithelial components of uterine and ovarian carcinosarcomas Journal of Clinical Oncology, 2017, 35, e17104-e17104.	0.8	0
183	Large germline next generation (NGS) sequencing panel of uterine serous carcinoma Journal of Clinical Oncology, 2017, 35, e13106-e13106.	0.8	0
184	A 12 multigene NGS panel to characterize molecular biotypes in endometrial cancer Journal of Clinical Oncology, 2018, 36, 5591-5591.	0.8	0
185	Differential copy number alteration profiles among gynecological malignancies Journal of Clinical Oncology, 2019, 37, e14744-e14744.	0.8	Ο
186	Translational study associated to a phase II study evaluating the activity of pazopanib in patients (pts) with advanced/metastatic liposarcoma (LPS): A joint Spanish Sarcoma Group (GEIS) and German Interdisciplinary Sarcoma Group (GISG) study Journal of Clinical Oncology, 2019, 37, 11067-11067.	0.8	0
187	Distribution and clinical role of KIT gene mutations in melanoma according to subtype: a study of 492 Spanish patients. European Journal of Dermatology, 2021, 31, 830-838.	0.3	0
188	Title is missing!. , 2019, 14, e0223341.		0
189	Title is missing!. , 2019, 14, e0223341.		0
190	Title is missing!. , 2019, 14, e0223341.		0
191	Title is missing!. , 2019, 14, e0223341.		0
192	Title is missing!. , 2019, 14, e0223341.		0
193	Title is missing!. , 2019, 14, e0223341.		0
194	Liquid biopsy: possibilities and limitations in uro-oncology Archivos Espanoles De Urologia, 2022, 75, 203-214.	0.1	0